Get started
Author

Kejun Li

1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
2021 · L. Wu, B. Chen, et al. · Annals of Oncology · 19
IRF1 transcriptionally up-regulates CXCL10 which increases CD8+ T cells infiltration in colorectal cancer
2024 · Wenyi Li, Kejun Li, et al. · International Immunopharmacology · 13
LncRNA SNHG3 discriminates rheumatoid arthritis from healthy individuals and regulates inflammatory response and oxidative stress via modulating miR-128-3p
2024 · Kejun Li, Wei Liu, et al. · Modern Rheumatology · 5
P40.14 Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
2021 · L. Wu, X. Pu, et al. · Journal of Thoracic Oncology · 3
The clinical value of echocardiography combined with transabdominal vascular ultrasound in the diagnosis of different types of aortic dissection
2023 · Weihua Zhong, Kejun Li, et al. · Journal of Clinical Ultrasound · 2
7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial
2022 · C. Zhou, A. Xiong, et al. · Annals of Oncology · 2
PDF
P16.04 A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer
2021 · L. Wu, X. Pu, et al. · Journal of Thoracic Oncology · 2
Enhancer of Zeste Homolog 2 (ezh2) Inhibitor Shr2554 in Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl): Updated Outcomes From the First‐in‐human Phase 1 Study
2023 · Y. Song, J. Zhu, et al. · Hematological Oncology · 1
PDF
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
2022 · L. Wu, B. Chen, et al. · Journal of Thoracic Oncology · 1
P51.03 Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial
2021 · C. Zhou, A. Xiong, et al. · Journal of Thoracic Oncology · 1
PDF
1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)
2021 · L. Wu, Z. Wu, et al. · Annals of Oncology · 1
PDF
P76.24 A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)
2021 · L. Wu, Z. Wu, et al. · Journal of Thoracic Oncology · 1
PDF
Myeloid-derived IL6/JAK/STAT3 signaling establishes a spatially organized immunosuppressive niche to fuel colitis-associated carcinogenesis
2026 · Yuehong Chen, Shunyi Wang, et al. · Journal of Translational Medicine
A USP8-targeting nanoamplifier synergizes with radiotherapy to remodel the immunosuppressive tumor microenvironment in lung cancer
2026 · Junjian Deng, Peiyi Luo, et al. · Materials Today Bio
PDF
Abstract CT116: A first-in-human phase 1 study on the safety, PK, receptor occupancy, and pharmacodynamic markers of SPX-303, a first-in-class LILRB2×PD-L1 bispecific antibody
2025 · Justin Moser, Hao Xie, et al. · Cancer Research
EP03.05-06 Identification of Oncogenic Non-coding Regions Inducing the ANKZF1 Expression in Lung Cancer by a Multi-omics Website Omics3D
2023 · C. Lian, X. Han, et al. · Journal of Thoracic Oncology
PDF
P76.63 Dacomitinib Induces a Drastic Response in Metastatic Brain Lesions of Patients with EGFR-mutant Non-small-cell Lung Cancer: A Brief Report
2021 · L. Wu, W. Peng, et al. · Journal of Thoracic Oncology
PDF
P011 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
2018 · D. Wu, J. Liu, et al. · Journal of Thoracic Oncology
PDF
P1.01-96 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
2018 · D. Wu, J. Liu, et al. · Journal of Thoracic Oncology
Works count: 19
Citation count: 50
H-index: 3
I10-index: 2
Year
Topic
Type